Globus Medical, Inc.
Rank #164Op. LeverageGMED · NYSE · Healthcare
Globus Medical, Inc. (GMED) — Rank #164 by gross profitability (GP/assets 0.36) · ROE 11.3% · Piotroski F-Score 8 / 9.
As-of 2026-09-15 · CIK 0001237831 · all metrics point-in-time as of the filing date.
About
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Show moreShow less
The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc.
was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- globusmedical.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$10.02B
P/E (annual)
19.0
P/S (annual)
3.4
P/B
2.1
P/OCF (annual)
13.3
Shareholder Yield
0.6%
Employees
6,000
Industry
Medical Devices
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
5.8%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -0.6% — per-share value needs a total required return of 5.2% once share-count change is priced in.
vs. own 6-year median revenue growth: 19.0%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
1.6%
r = 10% (base)
5.8%
r = 12%
9.4%
Net debt / market cap: -8.2%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Operating margin expansion and free cash flow are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.36
Primary signal (Novy-Marx).
11th of 17 SIC 3841 peers
Return on equity
11.3%
Gross margin
67.4%
8th of 17 SIC 3841 peers
Revenue growth (YoY)
16.7%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
42.2%
Revenue CAGR (5Y)
30.1%
Earnings CAGR (3Y)
41.4%
FCF CAGR (3Y)
78.0%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.15
1st of 16 SIC 3841 peers (best = lowest)
Current ratio
4.62×
3rd of 17 SIC 3841 peers
Quick ratio
2.69×
Net cash
$840.50M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$588.77M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.09
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.7%
Stock-based comp intensity.
Piotroski F-Score
F-Score
8 / 9
Fundamental-strength score (0-9).